Maurizio Scaltriti

Maurizio Scaltriti

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4375476
-
person_outline Maurizio Scaltriti's MOST POPULAR ARTICLES
1-) NTRK fusion-positive cancers and TRK inhibitor therapyE Cocco, M Scaltriti, A DrilonNature reviews Clinical oncology 15 (12), 731-747, 201811722018
2-) The epidermal growth factor receptor pathway: a model for targeted therapyM Scaltriti, J BaselgaClinical cancer research 12 (18), 5268-5272, 200611612006
3-) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activityS Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ...Cancer cell 19 (1), 58-71, 201110202011
4-) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerM Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ...Journal of the National Cancer Institute 99 (8), 628-638, 200710702007
5-) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutationsV Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ...Cancer research 68 (19), 8022-8030, 20089232008